Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4212435 | Respiratory Medicine | 2008 | 4 Pages |
Abstract
SummaryPulmonary Langerhans cell histiocytosis (LCH) is an uncommon cause of interstitial lung disease. Corticosteroids and chemotherapeutic agents are frequently used to treat symptomatic patients but their efficacy is unclear. We describe a 66-year-old with biopsy-proven pulmonary and systemic LCH, whose pulmonary abnormalities responded dramatically to treatment with 2-chlorodeoxyadenosine (2-CdA). We propose that, in selected cases, 2-CdA should be considered in the management of pulmonary LCH.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Michelle R. Aerni, Marie Christine Aubry, Jeffery L. Myers, Robert Vassallo,